Full View

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

T Yang, Z Kong, W Ma - Human Vaccines & Immunotherapeutics, 2021 - Taylor & Francis
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …
被引用次数：81 相关文章

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.

T Yang, Z Kong, W Ma - Human Vaccines & Immunotherapeutics, 2020 - europepmc.org
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …
[HTML] nih.gov

[HTML][HTML] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

T Yang, Z Kong, W Ma - Human Vaccines & Immunotherapeutics, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

T Yang, Z Kong, W Ma - Human vaccines & …, 2021 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.

T Yang, Z Kong, W Ma - Human Vaccines & Immunotherapeutics, 2020 - europepmc.org
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy.
Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and …